Panton-Valentine leukocidin antibodies for the treatment of MRSA skin infections?

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 4, 2011, Pages 389-392

  Otto, Michael ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

drug development; MRSA; Panton Valentine leukocidin; skin infections; Staphylococcus aureus

Indexed keywords

PANTON VALENTINE LEUKOCIDIN; STAPHYLOCOCCUS VACCINE; TOXIN ANTIBODY;

ANTIBIOTIC PROPHYLAXIS; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; BACTERIAL SKIN DISEASE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CLINICAL FEATURE; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; RECURRENT INFECTION; REVIEW; SOFT TISSUE INFECTION; VACCINATION;

EID: 79955120817     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/era.09.12     Document Type: Review

References (36)

1. Hermos CR, Yoong P, Pier GB. High levels of antibody to Panton-Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin. Infect. Dis. 51(10), 1138-1146 (2010).
2. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15), 1763-1771 (2007). (Pubitemid 47598444)
3. DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J. Clin. Invest. 119(9), 2464-2474 (2009).
4. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375(9725), 1557-1568 (2010).
5. Diep BA, Gill SR, Chang RF et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367(9512), 731-739 (2006). (Pubitemid 43326291)
6. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355(7), 666-674 (2006).
7. Otto M. Looking toward basic science for potential drug discovery targets against community-associated MRSA. Med. Res. Rev. 30(1), 1-22 (2010).
8. Gillet Y, Issartel B, Vanhems P et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359(9308), 753-759 (2002). (Pubitemid 34215075)
9. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton- Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9(8), 978-984 (2003). (Pubitemid 36944519)
10. Brown EL, Bowden MG, Bryson RS et al. Pediatric antibody response to community-acquired Staphylococcus aureus infection is directed to Panton-Valentine leukocidin. Clin. Vaccine Immunol. 16(1), 139-141 (2009).
11. Verkaik NJ, de Vogel CP, Boelens HA et al. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J. Infect. Dis. 199(5), 625-632 (2009).
12. Croze M, Dauwalder O, Dumitrescu O et al. Serum antibodies against Panton- Valentine leukocidin in a normal population and during Staphylococcus aureus infection. Clin. Microbiol. Infect. 15(2), 144-148 (2009).
13. Voyich JM, Braughton KR, Sturdevant DE et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J. Immunol. 175(6), 3907-3919 (2005). (Pubitemid 41292051)
14. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu. Rev. Microbiol. 64, 143-162 (2010).
15. Adem PV, Montgomery CP, Husain AN et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N. Engl. J. Med. 353(12), 1245-1251 (2005). (Pubitemid 41345946)
16. Miller LG, Perdreau-Remington F, Rieg G et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352(14), 1445-1453 (2005). (Pubitemid 40471452)
17. Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40(1), 100-107 (2005). (Pubitemid 40053465)
18. Diep BA, Otto M. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 16(8), 361-369 (2008).
19. Labandeira-Rey M, Couzon F, Boisset S et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315(5815), 1130-1133 (2007). (Pubitemid 46328024)
20. Brown EL, Dumitrescu O, Thomas D et al. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 15(2), 156-164 (2008).
21. Tseng CW, Kyme P, Low J et al. Staphylococcus aureus Panton-Valentine leukocidin contributes to inflammation and muscle tissue injury. PLoS ONE 4(7), e6387 (2009).
22. Bubeck Wardenburg J, Palazzolo- Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis. 198(8), 1166-1170 (2008).
23. Voyich JM, Otto M, Mathema B et al. Is Panton-Valentine Leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis. 194(12), 1761-1770 (2006). (Pubitemid 44902009)
24. Montgomery CP, Daum RS. Transcription of inflammatory genes in the lung after infection with community-associated methicillin-resistant Staphylococcus aureus: a role for Panton- Valentine leukocidin? Infect. Immun. 77(5), 2159-2167 (2009).
25. Olsen RJ, Kobayashi SD, Ayeras AA et al. Lack of a major role of Staphylococcus aureus Panton-Valentine leukocidin in lower respiratory tract infection in nonhuman primates. Am. J. Pathol. 176(3), 1346-1354 (2010).
26. Bubeck Wardenburg J, Bae T, Otto M, DeLeo FR, Schneewind O. Poring over pores: a-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med. 13(12), 1405-1406 (2007). (Pubitemid 350224232)
27. Villaruz AE, Wardenburg JB, Khan BA et al. A point mutation in the agr locus rather than expression of the Panton- Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J. Infect. Dis. 200(5), 724-734 (2009).
28. Loffler B, Hussain M, Grundmeier M et al. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 6(1), e1000715 (2010).
29. Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205(2), 287-294 (2008). (Pubitemid 351281594)
30. Li M, Cheung GY, Hu J et al. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J. Infect. Dis. 202(12), 1866-1876 (2010).
31. Cremieux AC, Dumitrescu O, Lina G et al. Panton-Valentine leukocidin enhances the severity of community-associated methicillin-resistant Staphylococcus aureus rabbit osteomyelitis. PLoS ONE 4(9), e7204 (2009).
32. Diep BA, Chan L, Tattevin P et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc. Natl Acad. Sci. USA 107(12), 5587-5592 (2010).
33. Bae IG, Tonthat GT, Stryjewski ME et al. Presence of genes encoding the Panton- Valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J. Clin. Microbiol. 47(12), 3952-3957 (2009).
34. Yoong P, Pier GB. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc. Natl Acad. Sci. USA 107(5), 2241-2246 (2010).
35. Wang R, Braughton KR, Kretschmer D et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 13(12), 1510-1514 (2007). (Pubitemid 350224240)
36. Kennedy AD, Bubeck Wardenburg J, Gardner DJ et al. Targeting of a-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 202(7), 1050-1058 (2010).